Ruiying Liang; Fangfang Chen; Yan Zhao; Ju Wang; Decai Zhao; Jiejun Yu; Houlin Tang; Jian Li; Zhongfu Liu; Ruiying Liang; Fangfang Chen; Yan Zhao; Ju Wang; Decai Zhao; Jiejun Yu; Houlin Tang; Jian Li; Zhongfu Liu

doi:10.46234/ccdcw2025.138

[1]

Yu G, Li TL, Wang ZH, Nengge AJ, Shama BD, Jike CN, et al. Analysis of the characteristics of HIV/AIDS patients reported in Liangshan Prefecture between 2017 and 2019. Chin J AIDS STD 2021;27(10):1152-3. https://link.cnki.net/doi/10.13419/j.cnki.aids.2021.10.24. (In Chinese).

[2]

Deng L, Liu ZF, Zhang SZ, Dou ZH, Wang QX, Ma Y, et al. Survival time and related influencing factors of AIDS patients in Liangshan prefecture, Sichuan province, during 2008-2013. Chin J Epidemiol 2015;36(6):569 − 75.

[3]

Liu ZF, Tang XF, Liu YF, Zhang LL, Yang YH, Zheng YL, et al. HIV prevention and health poverty alleviation - Liangshan prefecture, Sichuan Province, China, 2017-2020. China CDC Wkly 2021;3(48):1031 − 5.

[4]

Xu JL, Jike C, Ma Y, Yu G, Wang J, Wang K, et al. Effects and associated factors of HIV/AIDS anti-retroviral therapy in Liangshan Yi Autonomous Prefecture, Sichuan Province. Chin J Prev Med 2018;52(6):668 − 72.

[5]

Wu ZY, Zhao Y, Ge XM, Mao YR, Tang ZZ, Shi CX, et al. Simplified HIV Testing and Treatment in China: analysis of mortality rates before and after a structural intervention. PLoS Med 2015;12(9):e1001874.

[6]

Liu YF, Tang XF, Han MJ, Jike CN, Yang YH, Qu MX, et al. Achievements and prospects of AIDS Prevention and Health Poverty Alleviation in Liangshan Prefecture. Chin J AIDS STD 2022;28(12):1339-44. https://link.cnki.net/doi/10.13419/j.cnki.aids.2022.12.01. (In Chinese).

[7]

Zhang FJ, Dou ZH, Ma Y, Zhang Y, Zhao Y, Zhao DC, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011;11(7):516 − 24.

[8]

Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 2017;46(1):348 − 55.

[9]

Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, et al. The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. Lancet HIV 2021;8(3):e158 − 65.

[10]

Cao W, Hsieh E, Li TS. Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges. Curr HIV/AIDS Rep 2020;17(1):26 − 34.

[11]

Shu R, Lyu H, Ma GY, Chen HY, Zhou Y, Zhou JJ, et al. Trends in HIV/AIDS-related mortality and the impact of antiretroviral treatment strategies in Lu’an City: a comprehensive analysis. Med Sci Monit 2024;30(1):e944727.

[12]

Mugenyi L, Nanfuka M, Byawaka J, Agaba C, Mijumbi A, Kagimu D, et al. Effect of universal test and treat on retention and mortality among people living with HIV-infection in Uganda: an interrupted time series analysis. PLoS One 2022;17(5):e0268226.

[13]

Wu XS, Wu GH, Ma P, Wang RG, Li LH, Sun YH, et al. Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysis. Infect Dis Poverty 2023;12(1):73.

[14]

Ross J, Sinayobye JD, Yotebieng M, Hoover DR, Shi QH, Ribakare M, et al. Early outcomes after implementation of treat all in Rwanda: an interrupted time series study. J Int AIDS Soc 2019;22(4):e25279.

[15]

Edwards JK, Cole SR, Breger TL, Filiatreau LM, Zalla L, Mulholland GE, et al. Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population. Clin Infect Dis 2022;75(5):867 − 74.